This report studies Pulmonary Arterial Hypertension (PAH) Drugs in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering Actelion Pharmaceuticals DAIICHI SANKYO GlaxoSmithKline Novartis United Therapeutics AADi Actelion Pharmaceuticals Aires Pharmaceuticals Arena Pharmaceuticals Asklepion Pharmaceuticals AstraZeneca Bayer Healthcare Berlin Cures BIAL Eiger BioPharmaceuticals By types, the market can be split into Inhalation Injectables Oral administration By Application, the market can be split into ERAs Prostacyclin analogs PDE inhibitors sGC stimulators By Regions, this report covers (we can add the regions/countries as you want) North America China Europe Southeast Asia Japan India
Table of Contents Global Pulmonary Arterial Hypertension (PAH) Drugs Market Professional Survey Report 2017 1 Industry Overview of Pulmonary Arterial Hypertension (PAH) Drugs 1.1 Definition and Specifications of Pulmonary Arterial Hypertension (PAH) Drugs 1.1.1 Definition of Pulmonary Arterial Hypertension (PAH) Drugs 1.1.2 Specifications of Pulmonary Arterial Hypertensi
